New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - powder for infusion - 2 g - active: ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for infusion - 2 g - active: ceftriaxone sodium 2.158 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - infections caused by pathogens sensitive to ceftriaxone e.g.: - sepsis; - meningitis; - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms; - renal and urinary tract infections; - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; - genital infections, including gonorrhoea. - perioperative prophylaxis of infections.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 1 g in 50 ml - ceftriaxone for injection and dextrose injection is indicated for the treatment of the following infections when caused by susceptible bacteria. lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens . skin and skin structure infections caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes, viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii 1, pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis 1 or peptostreptococcus species. complicated and uncomplicated urinary tract infections caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae . pelvic inflammatory disease caused by neisseria gono

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for injection - 2 g - active: ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)

United States - English - NLM (National Library of Medicine)

sandoz gmbh - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

United States - English - NLM (National Library of Medicine)

sandoz inc - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 250 mg - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus,

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - powder for injection - 2 g - active: ceftriaxone sodium 2.385 g (present as 2.385g ceftriaxone sodium*3.5h2o. eq 2.1586g of ceft. sodium anh or 2g ceftriaxone anh) - infections caused by pathogens sensitive to ceftriaxone e.g.: · sepsis; · meningitis; · abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts); · infections of the bones, joints, soft tissue, skin and of wounds; · infections in patients with impaired defence mechanisms; · renal and urinary tract infections; · respiratory tract infections, particularly pneumonia, and ear, nose and throat infections; · genital infections, including gonorrhoea. · perioperative prophylaxis of infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftriaxone sodium 2.39 g equivalent to ceftriaxone 2 g - powder for injection - 2 g - active: ceftriaxone sodium 2.39 g equivalent to ceftriaxone 2 g - ceftriaxone sodium is indicated for the treatment of lower respiratory tract infections when caused by susceptible aerobic organisms

Canada - English - Health Canada

fresenius kabi canada ltd - ceftriaxone (ceftriaxone sodium) - powder for solution - 2g - ceftriaxone (ceftriaxone sodium) 2g - third generation cephalosporins

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd);  ;   - powder for injection - 2 g - active: ceftriaxone sodium 2.386 g (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)